Screener
Cullinan Therapeutics, Inc. CGEM Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Cullinan Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s debt-to-equity?
- Cullinan Therapeutics, Inc. (CGEM) reported debt-to-equity of 0× in Q4 2025.
- How has Cullinan Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Cullinan Therapeutics, Inc.'s debt-to-equity increased by 83.3% year-over-year, from 0× to 0×.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s debt-to-equity has grown at a 19.8% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Cullinan Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude